Trial Profile
An open-label, nonrandomized, crossover study to evaluate the safety, efficacy and pharmacokinetics of Ponatinib alone and in combination with Rifampin in healthy volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Oct 2015
Price :
$35
*
At a glance
- Drugs Ponatinib (Primary) ; Rifampicin
- Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Pharmacokinetics
- Sponsors ARIAD Pharmaceuticals
- 29 Oct 2015 New trial record
- 01 Sep 2015 Results were published in Clinical Pharmacology in Drug Development.